SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

RCHA RSS Feed
Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: Axeman, RocknRoll, surf1944, PepsiMan, mikewazowski
Search This Board: 
Last Post: 9/24/2017 2:52:35 AM - Followers: 323 - Board type: Free - Posts Today: 1





http://www.richpharmaceuticals.com/ 

http://www.otcmarkets.com/stock/RCHA/profile

 
RCHA Patent for Treatment of Hodgkin’s Lymphoma

http://www.richpharmaceuticals.com/wp-content/uploads/2014/10/Rich-10_13_14-HL-Patent-Ownership-Rights.pdf

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,
utility patent application number 61998397, entitled COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF HODGKIN’S LYMPHOMA.
 

Facts About Hodgkins Lymphoma

Description of Hodgkins Lymphoma. Hodgkins Lymphoma is a cancer of the lymphatic system. Malignant Reed Sternberg cells invade and destroy the architecture of the lymph nodes and infiltrate major organs such as the liver and spleen in more advanced cases (Stages III and IV). Treatment options for Hodgkins Lymphoma are chemotherapy, radiotherapy or chemotherapy plus radiotherapy. More difficult cases may require high dose chemotherapy and stem cell transplant. In addition to the stage of the disease other factors such as age, general health and location of the disease are considered important in treatment decisions. In recent years PET/CT scans have been helpful in determining the extent of Hodgkins disease and assessing how well treatment is working. In some patients Hodgkins may never go away completely and regular treatments are required to control the disease while others experience relapses. Nowadays chemotherapy plus radiotherapy to involved areas is considered as standard treatment for patients with early stage Hodgkins Lymphoma (Stages I and II) and the incidence of survival in the U.S. after 5-years is about 90%. The 5-year survival rate for stage III patients is about 80% while it is 65% for stage IV patients. Due to long term adverse effects such as secondary malignancies causing both morbidity and mortality, the role of radiotherapy has been questioned and other means of treatment are being sought.

Incidence of Hodgkins Lymphoma. This disease is a cancer that is found most frequently in two different age groups (15 to 35 and over 55) and occurs in both sexes although more common in males and individuals with HIV, and in the third decade of life.. The overall incidence of Hodgkins Lymphoma is 2.7 per 100,000 persons and in the U.S. 185,793 individuals were stricken with this disease in 2011. The worldwide estimate for treatment of Hodgkins Lymphoma is estimated to be $1 to 2 billion. The cause of Hodgkins Lymphoma is unknown but factors such as smoking and alcohol have been linked to this disease, and siblings of with parents with Hodgkins have an increased risk (2 to 5X) of developing this disease. The specific factors triggering the conversion of normal lymphocytes to Hodgkins Lymphoma cells is unknown.

Facts about AML

Acute Myelocytic Leukemia (AML)

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is the most common acute leukemia type that affects adults. Other names for AML that refer to the same disease are acute myeloid leukemia and acute myeloblastic leukemia. AML is sometimes referred to as acute myelo cancer, acute myelo leukemia and acute myeloid cancer.

What is Acute Myelocytic Leukemia (AML)?

AML is an aggressive form of cancer of the blood and the bone marrow, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal white blood cells. The myeloid blood stem cells of the bone marrow develop into abnormal, poorly formed myeloblasts and do not become healthy white blood cells.
The incidence of myeloblastic leukemia in the USA is of about 1 case in 100 000 persons per year during the first 20 years of life, with a later increase to around 20 cases in 100 000 persons per year for octogenarians. Myeloid leukemia progresses rapidly and can typically be fatal within weeks or months.

Acute Myelocytic Leukemia (AML) Symptoms

Most signs and symptoms of AML are caused by the decreased ability of the body to fight off infection due to the replacement of normal blood cells with leukemic cells.
The symptoms of myelogenous leukemia are generally vague and non-specific. All or some of the following symptoms may be experienced by the person affected:

• Lethargy, chronic fatigue
• Fever (usually of unknown origin)
• Shortness of breath
• Inexplicable weight loss
• Frequent infections
• Headaches
• Pale skin, skin rash
• Non-specific bone pain
• Easy bruising
• Unusual bleeding such as nose or gum bleeding
• Blood in urine or stools
• Enlarged lymph nodes and/or spleen
• Abdominal fullness

Other symptoms of myelo leukemia include anemia, tumors of leukemic cells in the lung, breast, brain, uterus, ovary, stomach or prostate.

 
RCHA Recent News
 

Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials

June 21, 2017

Dr. Numbenjapon specializes in medical oncology, hematology, and stem cell transplantation. He has over 14 years of experience in Hematology and Oncology.

“We are confident that Dr. Numbenjapon is the best and most qualified physician to head our research abroad, and look forward to his guidance as we embark on the next phase of our clinical studies,” said Ben Chang, CEO.

Now that Rich Pharmaceuticals has filed an IND (https://youtu.be/0CCtXc43a0I) with the FDA and re- ceived approval to start phase I/II (https://youtu.be/1WvlzbzKGqE), operations have progressed to the site level at Phramongkutklao Hospital and a full package has been submitted to the hospitals IRB (Review Board). "Rich Pharmaceuticals is pleased to have reached such a milestone and we look forward to patient enrollment at Phramongkutklao Hospital with the help of Dr. Numbenjapon," stated Mr. Chang.
 

Rich Pharmaceuticals Announces Institutional Review Board Submission

June 8, 2017

Beverly Hills, California - Rich Pharmaceuticals, Inc. (OTCPK: RCHA) (“Rich” or the “Company”), a bio- pharmaceutical Company focused on developing and commercializing innovative therapies in oncology an- nounced today that has filed its submission package to the Institutional Review Board (IRB) of Phramongkutklao Hospital in Bangkok, Thailand.

The submission is part of a process that leads to a study for the treatment of Acute Myelocytic Leukemia (AML) in refractory patients in a Phase I/II trial. “We are happy we’ve reached this milestone and we look forward to communicating further developments on this effort and other clinical milestones over time,” said Ben Chang, CEO.

The Company IRB submission was completed on May 31, 2017. An IRB is a group that is formally desig- nated to review and monitor biomedical research involving human patients. This submission is an integral to the Clinical Trial and drug approval process. 
 

Rich Pharmaceuticals Announces Clinical Site in Thailand

May 31, 2017

Beverly Hills, California - Rich Pharmaceuticals, Inc. (OTCPK: RCHA) (“Rich” or the “Company”), a bio- pharmaceutical company focused on developing and commercializing innovative therapies in oncology an- nounced today that it has selected a site and obtained investigator’s interest at Phramongkutklao Hospital in Bangkok, Thailand. Rich has engaged CMIC ASIA-PACIFIC, PTE. LTD. (“CMIC”) to assist in this project and they have already completed a site selection visit at Phramongkutklao Hospital, and the site has been cleared.

Rich and CMIC are preparing submission packages for the Hospital’s Internal Review Board (IRB) and the Thailand Food and Drug Administration (FDA). This package is near completion and the Company plans to submit it shortly. “The Company has purchased product liability insurance, the package is near completion and we hope to submit in the coming days,” said Ben Chang, CEO.

In cooperation with the Hospital, Rich is seeking to conduct a study for the treatment of Acute Myelocytic Leukemia (AML) in refractory patients in a Phase I/II trial. Acute Myelocytic Leukemia is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Because the incidence increases with age, it is expected that incidence will rise as population rises. 

 

Our Science

Rich Pharmaceuticals currently is focused on the clinical development of the chemical molecule TPA (12-O-tetradecanoylphorbol-13-acetate) for the treatment of acute myelogenous leukemia (AML). The Company has technical evidence to suggest that it may also be useful to treat other important diseases resulting in it being a widely used drug with major market potential.

TPA

TPA is a naturally occurring molecule that is isolated and purified from croton oil which is obtained from the seeds of Croton tiglium, a leafy shrub native to Southeast Asia. While this has been the major source of TPA for clinical studies conducted by Rich Company scientists recently devised a synthetic route for preparation of the drug which will ensure providing the necessary supply of highly pure drug for clinical use. TPA has characteristics that are unique to this chemical class including a potent ability to accelerate differentiation of the myeloid cell lines, HL-60 and THP-1, as well as mononuclear phagocytes from bone marrow and peripheral blood. The best characterized receptor for TPA is protein kinase C (PKC) which, once activated, induces substrate phosphorylation that propagates signals to the MAPK cascades. The effects of TPA on MAPK pathways may be particularly relevant to the differentiating and pro-apoptotic effects of TPA in certain cells. The capacity of TPA to activate PKC and to induce phenotypic changes characteristic of differentiation and/or apoptosis led investigators to study its effect in AML.

What Justifies the Use of TPA to Treat AML?

Acute myelogenous leukemia (AML) is an aggressive disease that requires urgent and intensive therapy. Patients diagnosed with AML are, on average, between 64 and 68 years of age. Patients over 60 treated with standard chemotherapy are cured of their disease less that 20 percent of the time. In addition, patients who develop AML after an antecedent hematologic disorder or prior leukemogenic chemotherapy/radiation have similarly poor outcomes as do patients whose disease is associated with specific cytogenetic and clinical features. Most patients diagnosed with AML have a poor prognosis. For patients with relapsed disease, no standard non-transplant therapy has demonstrated the capacity for cure and AML is often fatal.

In view of the above facts, it is obvious that new approaches to therapy are needed. The clinical studies completed and those currently in progress with TPA report feasibility and potential efficacy of this drug in patients with relapsed/refractory myeloid malignancies.


 
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

http://finance.yahoo.com/q/ks?s=WX+Key+Statistics
http://finance.yahoo.com/q?s=wx&ql=1
http://www.wuxiapptec.com/

 
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
Courtesy of Sibware: 
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110569310 
 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.
 

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 

AML 

It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.
 

RCHA Key DD Posts:
 
Key RCHA & WX:NYSE Relationship
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110555124
 
Respectfully, again, key with the Authorized Shares
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110551465
 
RCHA NEWS
 
http://finance.yahoo.com/q/h?s=RCHA+Headlines
http://www.richpharmaceuticals.com/category/news/
 
RCHA SEC FILINGS
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001504389&owner=exclude&count=40
 
http://www.richpharmaceuticals.com/contact-us/

Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003

E: info@richpharmaceuticals.com
 

 

Chart View


 
SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
RCHA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#20020   Most definitely. Rcha is getting ripe. Looks like Peddler22 09/24/17 02:52:35 AM
#20019   I was aware of the following but I PepsiMan 09/23/17 04:51:41 PM
#20018   Yes yes, I think we are in for Werbe 09/23/17 03:23:00 PM
#20016   RCHA moving up on the breakout boards Like the Jacque_Strap 09/22/17 05:49:26 PM
#20015   Greater numbers are to come. One word: Team. billionaire28 09/22/17 04:56:33 PM
#20014   RCHA Avg Volume (10 days) 17,972,476 Today 72,504,765 beer$$money 09/22/17 04:24:48 PM
#20013   Always the flippers ! They have zip wedman 09/22/17 04:12:13 PM
#20012   We had the momentum until the 911 trade billionaire28 09/22/17 04:00:04 PM
#20011   7 sellers are dumb.... still a bunch of masahirox 09/22/17 03:34:13 PM
#20010   And a little work! beer$$money 09/22/17 03:34:05 PM
#20008   One word: Team. billionaire28 09/22/17 03:28:18 PM
#20007   We're top 20 on the breakout boards masahirox 09/22/17 03:26:41 PM
#20006   Investors are eyeing RCHA. billionaire28 09/22/17 03:25:19 PM
#20005   Best volume day in months. Something is up!!! masahirox 09/22/17 03:22:36 PM
#20004   This could be setting up for cross or Jacque_Strap 09/22/17 03:20:00 PM
#20003   Also a no brainer because they just recently wedman 09/22/17 02:55:50 PM
#20002   You’ll soon understand, lol.. RocknRoll 09/22/17 02:52:45 PM
#20001   Absolutely PepsiMan, I'm with you. billionaire28 09/22/17 02:44:30 PM
#20000   This could breakout anytime. I used to PepsiMan 09/22/17 02:39:26 PM
#19999   Last chance to grab some at .007 before billionaire28 09/22/17 02:39:23 PM
#19998   8's falling fast. beer$$money 09/22/17 02:36:38 PM
#19997   We all make good and bad decisions but billionaire28 09/22/17 02:36:32 PM
#19996   GLTY to you as well RocknRoll ;-) PepsiMan 09/22/17 02:34:55 PM
#19995   When a certain someone showed up my vast RocknRoll 09/22/17 02:32:46 PM
#19994   Absolutely and he loves getting into winners. PepsiMan 09/22/17 02:30:28 PM
#19993   I see your coding problem but we all billionaire28 09/22/17 02:28:37 PM
#19991   He is good!! wedman 09/22/17 02:22:52 PM
#19990   You're welcome this is going to fly Tim111 09/22/17 02:19:39 PM
#19989   I am fighting signal problems. 911 Trade PepsiMan 09/22/17 02:12:41 PM
#19988   911 trade Tim111 09/22/17 02:07:44 PM
#19987   I like it. It's great to see we're Axeman 09/22/17 02:06:10 PM
#19986   Nice to see ;) billionaire28 09/22/17 02:06:06 PM
#19985   Steady as she goes. We are not PepsiMan 09/22/17 02:05:03 PM
#19984   Looking rather nice today RocknRoll. Volume is lookin PepsiMan 09/22/17 02:00:45 PM
#19983   Chart all of a sudden looks tasty masahirox 09/22/17 02:00:00 PM
#19982   Hey Sterling! It's great having you show PepsiMan 09/22/17 01:57:46 PM
#19981   Nice buy volume RCHA!! HallaDurg 09/22/17 01:55:58 PM
#19980   Axe, All these shares can be used to Jacque_Strap 09/22/17 01:55:33 PM
#19979   More to come. billionaire28 09/22/17 01:55:20 PM
#19978   Wow 25 mil block!!! Glad to see sterling here!!! masahirox 09/22/17 01:49:01 PM
#19977   You did lol Axeman 09/22/17 01:45:10 PM
#19976   .0007’s are paper thin, less than 1.2m RocknRoll 09/22/17 01:41:51 PM
#19975   PepsiMan, here with RCHA... stervc 09/22/17 01:41:35 PM
#19974   Looks good but we need news significant eye-popping Axeman 09/22/17 01:41:12 PM
#19973   Well as it stands right now 1,789,501 sold beer$$money 09/22/17 01:38:29 PM
#19972   Well looks like another 8k in affect. Probably Axeman 09/22/17 01:34:42 PM
#19971   I have had my running shoe's on and beer$$money 09/22/17 01:27:39 PM
#19970   Loading before the run! billionaire28 09/22/17 01:26:16 PM
#19969   10 milly slap on those 6's at 12:44 beer$$money 09/22/17 01:22:43 PM
#19968   Slap that ask! billionaire28 09/22/17 01:18:12 PM
PostSubject